BETA
Your AI-Trained Oncology Knowledge Connection!
Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.
Stay up to date on practice-changing data in community practice.
Tagraxofusp Yields Deep Responses as Frontline BPDCN Therapy
During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with blastic plasmacytoid dendritic cell neoplasm.
Read More
ICT01 Boosts AML Remission and Survival in EVICTION Trial
Abhishek Maiti, MD, discussed the EVICTION trial in AML and results presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Unique Diagnostic Profile for BPDCN Warrants Focus on Hematopathology
During a live event, Gary J. Schiller, MD, reviewed the diagnostics and characteristics of blastic plasmacytoid dendritic cell neoplasm.
Phase 1 GTB-3650 Trial Advances for CD33+ Malignancies
Cohort 1 of the GTB-3650 phase 1 trial completed with no safety issues observed in patients with CD33-expressing hematologic malignancies.
Study Indicates Early Resolution of CRS, Neurological Events After Axi-Cel
Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ciloleucel in large B-cell lymphoma.
Improving Quality of Life in LR-MDS Through Anemia Treatment
During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality of life in MDS.